Loading…

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation

Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2010-11, Vol.9 (1), p.305-305
Main Authors: Gravina, Giovanni L, Festuccia, Claudio, Marampon, Francesco, Popov, Vladimir M, Pestell, Richard G, Zani, Bianca M, Tombolini, Vincenzo
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3
cites
container_end_page 305
container_issue 1
container_start_page 305
container_title Molecular cancer
container_volume 9
creator Gravina, Giovanni L
Festuccia, Claudio
Marampon, Francesco
Popov, Vladimir M
Pestell, Richard G
Zani, Bianca M
Tombolini, Vincenzo
description Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.
doi_str_mv 10.1186/1476-4598-9-305
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A244673820</galeid><doaj_id>oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca</doaj_id><sourcerecordid>A244673820</sourcerecordid><originalsourceid>FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEoqVw5oYsOHBKa8dOYl-Qti0flSq4wNly7PGuV4m92Alofwd_uM5uWXVRkQ-2Zt55xvY7RfGa4HNCeHNBWNuUrBa8FCXF9ZPi9BB5-uB8UrxIaY0xaXnLnhcnFSGYt1ycFn8uXejD0mnVo6hGF7zqAdkQ0bgCNCVAwaLrrws0wLja9mNUPlmIKiecX7nOjSEmpBLy8BulnB5hud3VD8FM_Y44I8ZpyLEIaRN8rh0D0isYQm4S1WaLlDe5vXE7_cvimVV9glf3-1nx49PH71dfyttvn2-uFrdl12Ixlk3T4Y5S3HTaMNMq0dUtrajQRlUdY7VqKDYGiBCKUmoZCFvXyrbAWkwwUfSsuNlzTVBruYluUHErg3JyFwhxKVUcne5BQqUwxm3FKdes5kYwoKzWilnONNEz68OetZm6AYwGn_-iP4IeZ7xbyWX4JensCqEZcLkHdC78B3Cc0WGQs8FyNliKDKoz5P39LWL4OUEa5eCShr5XHsKUZHafcMxJk5Vv_1GuwxSz-UkKXFUsK2fcu71omYdCOm9D7qxnpFxUjDUt5RXOqvNHVHkZGJwOHqzL8aOCi32BjiGlCPbwSoLlPNaPvOvNw9896P_OMb0Dsmz1BQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902248745</pqid></control><display><type>article</type><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central Free</source><creator>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</creator><creatorcontrib>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</creatorcontrib><description>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</description><identifier>ISSN: 1476-4598</identifier><identifier>EISSN: 1476-4598</identifier><identifier>DOI: 10.1186/1476-4598-9-305</identifier><identifier>PMID: 21108789</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; DNA methylation ; DNA Modification Methylases - antagonists &amp; inhibitors ; DNA Modification Methylases - metabolism ; Enzyme inhibitors ; Enzyme Inhibitors - therapeutic use ; Epigenesis, Genetic - drug effects ; Health aspects ; Humans ; Medical research ; Methyltransferases ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - radiotherapy ; Physiological aspects ; Proteins ; Radiation, Ionizing ; Radiotherapy ; Review</subject><ispartof>Molecular cancer, 2010-11, Vol.9 (1), p.305-305</ispartof><rights>COPYRIGHT 2010 BioMed Central Ltd.</rights><rights>2010 Gravina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2010 Gravina et al; licensee BioMed Central Ltd. 2010 Gravina et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001713/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/902248745?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21108789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gravina, Giovanni L</creatorcontrib><creatorcontrib>Festuccia, Claudio</creatorcontrib><creatorcontrib>Marampon, Francesco</creatorcontrib><creatorcontrib>Popov, Vladimir M</creatorcontrib><creatorcontrib>Pestell, Richard G</creatorcontrib><creatorcontrib>Zani, Bianca M</creatorcontrib><creatorcontrib>Tombolini, Vincenzo</creatorcontrib><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><title>Molecular cancer</title><addtitle>Mol Cancer</addtitle><description>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</description><subject>Animals</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>DNA methylation</subject><subject>DNA Modification Methylases - antagonists &amp; inhibitors</subject><subject>DNA Modification Methylases - metabolism</subject><subject>Enzyme inhibitors</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Epigenesis, Genetic - drug effects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Medical research</subject><subject>Methyltransferases</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - radiotherapy</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Radiation, Ionizing</subject><subject>Radiotherapy</subject><subject>Review</subject><issn>1476-4598</issn><issn>1476-4598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kk1v1DAQhiMEoqVw5oYsOHBKa8dOYl-Qti0flSq4wNly7PGuV4m92Alofwd_uM5uWXVRkQ-2Zt55xvY7RfGa4HNCeHNBWNuUrBa8FCXF9ZPi9BB5-uB8UrxIaY0xaXnLnhcnFSGYt1ycFn8uXejD0mnVo6hGF7zqAdkQ0bgCNCVAwaLrrws0wLja9mNUPlmIKiecX7nOjSEmpBLy8BulnB5hud3VD8FM_Y44I8ZpyLEIaRN8rh0D0isYQm4S1WaLlDe5vXE7_cvimVV9glf3-1nx49PH71dfyttvn2-uFrdl12Ixlk3T4Y5S3HTaMNMq0dUtrajQRlUdY7VqKDYGiBCKUmoZCFvXyrbAWkwwUfSsuNlzTVBruYluUHErg3JyFwhxKVUcne5BQqUwxm3FKdes5kYwoKzWilnONNEz68OetZm6AYwGn_-iP4IeZ7xbyWX4JensCqEZcLkHdC78B3Cc0WGQs8FyNliKDKoz5P39LWL4OUEa5eCShr5XHsKUZHafcMxJk5Vv_1GuwxSz-UkKXFUsK2fcu71omYdCOm9D7qxnpFxUjDUt5RXOqvNHVHkZGJwOHqzL8aOCi32BjiGlCPbwSoLlPNaPvOvNw9896P_OMb0Dsmz1BQ</recordid><startdate>20101125</startdate><enddate>20101125</enddate><creator>Gravina, Giovanni L</creator><creator>Festuccia, Claudio</creator><creator>Marampon, Francesco</creator><creator>Popov, Vladimir M</creator><creator>Pestell, Richard G</creator><creator>Zani, Bianca M</creator><creator>Tombolini, Vincenzo</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20101125</creationdate><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><author>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>DNA methylation</topic><topic>DNA Modification Methylases - antagonists &amp; inhibitors</topic><topic>DNA Modification Methylases - metabolism</topic><topic>Enzyme inhibitors</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Epigenesis, Genetic - drug effects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Medical research</topic><topic>Methyltransferases</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - radiotherapy</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Radiation, Ionizing</topic><topic>Radiotherapy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gravina, Giovanni L</creatorcontrib><creatorcontrib>Festuccia, Claudio</creatorcontrib><creatorcontrib>Marampon, Francesco</creatorcontrib><creatorcontrib>Popov, Vladimir M</creatorcontrib><creatorcontrib>Pestell, Richard G</creatorcontrib><creatorcontrib>Zani, Bianca M</creatorcontrib><creatorcontrib>Tombolini, Vincenzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecular cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gravina, Giovanni L</au><au>Festuccia, Claudio</au><au>Marampon, Francesco</au><au>Popov, Vladimir M</au><au>Pestell, Richard G</au><au>Zani, Bianca M</au><au>Tombolini, Vincenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</atitle><jtitle>Molecular cancer</jtitle><addtitle>Mol Cancer</addtitle><date>2010-11-25</date><risdate>2010</risdate><volume>9</volume><issue>1</issue><spage>305</spage><epage>305</epage><pages>305-305</pages><issn>1476-4598</issn><eissn>1476-4598</eissn><abstract>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21108789</pmid><doi>10.1186/1476-4598-9-305</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1476-4598
ispartof Molecular cancer, 2010-11, Vol.9 (1), p.305-305
issn 1476-4598
1476-4598
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca
source Access via ProQuest (Open Access); PubMed Central Free
subjects Animals
Cancer
Cancer therapies
Care and treatment
Chemotherapy
DNA methylation
DNA Modification Methylases - antagonists & inhibitors
DNA Modification Methylases - metabolism
Enzyme inhibitors
Enzyme Inhibitors - therapeutic use
Epigenesis, Genetic - drug effects
Health aspects
Humans
Medical research
Methyltransferases
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - radiotherapy
Physiological aspects
Proteins
Radiation, Ionizing
Radiotherapy
Review
title Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A07%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20rationale%20for%20the%20use%20of%20DNA%20methyltransferase%20inhibitors%20as%20new%20strategy%20for%20modulation%20of%20tumor%20response%20to%20chemotherapy%20and%20radiation&rft.jtitle=Molecular%20cancer&rft.au=Gravina,%20Giovanni%20L&rft.date=2010-11-25&rft.volume=9&rft.issue=1&rft.spage=305&rft.epage=305&rft.pages=305-305&rft.issn=1476-4598&rft.eissn=1476-4598&rft_id=info:doi/10.1186/1476-4598-9-305&rft_dat=%3Cgale_doaj_%3EA244673820%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=902248745&rft_id=info:pmid/21108789&rft_galeid=A244673820&rfr_iscdi=true